To include your compound in the COVID-19 Resource Center, submit it here.

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 4/9 cls
Actelion Ltd. (SIX:ATLN) UBS Martin Wales Upgrade Buy (from neutral) 3% CHF49.85
Wales said he thinks the shares have been oversold since Tracleer bosentan failed in the Phase III BUILD-3 trial to treat idiopathic pulmonary fibrosis (IPF) (see BioCentury, March 8). However, Wales lowered his target to CHF55 from CHF58 to reflect a bearish view on the company's pipeline and weaker sales for Ventavis iloprost, an inhaled prostacyclin

Read the full 952 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers